Roscovitine (CYC202)

For research use only. Not for use in humans.

目录号：S1153 别名： Seliciclib, R-roscovitine

CAS No. 186692-46-6

Roscovitine (CYC202, Seliciclib, R-roscovitine)是一种有效的，选择性CDK抑制剂，作用于Cdc2，CDK2和CDK5时，无细胞试验中IC50分别为0.65 μM，0.7 μM和0.16 μM，对CDK4/6几乎没有作用。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1573.18	现货
10mg	RMB 1212.83	现货
25mg	RMB 2104.83	现货
50mg	RMB 3829.77	现货
200mg	RMB 7938.98	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达全国免运费分装免费

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Roscovitine (CYC202)发表文献103篇：

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Cell, 2014, 20;159(5):1126-1139.

PubMed: 25416950 ( click the link to review the publication )

Cell, 2013, 21;155(5):1088-103.

PubMed: 24267891 ( click the link to review the publication )

Nat Commun, 2022, 13(1):668

PubMed: 35115540 ( click the link to review the publication )

Exp Neurol, 2022, S0014-4886(22)00048-6

PubMed: 35218707 ( click the link to review the publication )

Nucleic Acids Res, 2021, 49(13):7492-7506

PubMed: 34197599 ( click the link to review the publication )

EMBO J, 2021, e99692

PubMed: 33856059 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:662868

PubMed: 34589478 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(17)9648

PubMed: 34502552 ( click the link to review the publication )

Life Sci, 2021, 269:119062

PubMed: 33476635 ( click the link to review the publication )

Toxicol Lett, 2021, 341:68-79

PubMed: 33548343 ( click the link to review the publication )

Elife, 2020, 7;9:e44571

PubMed: 32255427 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):197

PubMed: 32994405 ( click the link to review the publication )

J Mol Cell Biol, 2020, 12(8):644-653

PubMed: 31065693 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:845

PubMed: 33015044 ( click the link to review the publication )

Mol Cell Biol, 2020, 40(4)

PubMed: 31791978 ( click the link to review the publication )

PLoS One, 2020, 15(6):e0234708

PubMed: 32555680 ( click the link to review the publication )

J Pain Res, 2020, 13:2113-2124

PubMed: 32903807 ( click the link to review the publication )

J Biomater Sci Polym Ed, 2020, 1-10

PubMed: 33187457 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01403-y

PubMed: 32712628 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4027

PubMed: 32788676 ( click the link to review the publication )

Bone, 2020, 131:115153

PubMed: 31730830 ( click the link to review the publication )
Reprod Domest Anim, 2020, 55(3):351-363

PubMed: 31903647 ( click the link to review the publication )

Mol Cell, 2019, 73(4):670-683.e12

PubMed: 30639241 ( click the link to review the publication )

EMBO J, 2019, 38(19):e101704

PubMed: 31429971 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(37):18561-18570

PubMed: 31451657 ( click the link to review the publication )

PLoS Biol, 2019, 17(8):e3000203

PubMed: 31430272 ( click the link to review the publication )

J Cell Biol, 2019, 218(7):2113-2123

PubMed: 31123184 ( click the link to review the publication )

J Cell Biol, 2019, 218(9):2865-2875

PubMed: 31366665 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-3374

PubMed: 31551363 ( click the link to review the publication )

Oncogene, 2019, 38(25):4948-4961

PubMed: 30842588 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Front Immunol, 2019, 10:1554

PubMed: 31354714 ( click the link to review the publication )

Development, 2019, 146(23)dev182519

PubMed: 31704793 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1520-1532

PubMed: 31243099 ( click the link to review the publication )

Neurobiol Dis, 2019, 126:47-61

PubMed: 29944965 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14827

PubMed: 31314915 ( click the link to review the publication )

J Virol, 2019, 93(3)e01803-18

PubMed: 30404803 ( click the link to review the publication )

ACS Chem Neurosci, 2019, 10(4):1992-2003

PubMed: 30351911 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz135

PubMed: 31187143 ( click the link to review the publication )

Reprod Fertil Dev, 2019, 31(3):473-481

PubMed: 30301509 ( click the link to review the publication )

J Exp Med, 2019, 216(12):2819-2837

PubMed: 31515281 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Mol Cell, 2018, 69(3):371-384

PubMed: 29395061 ( click the link to review the publication )
Nat Commun, 2018, 9(1):2678

PubMed: 29992957 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3613

PubMed: 30190500 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(8):1913-1918

PubMed: 29434041 ( click the link to review the publication )

Cell Rep, 2018, 25(9):2605-2616

PubMed: 30485823 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10.1093/jmcb/mjy033

PubMed: 29771379 ( click the link to review the publication )

J Cancer, 2018,

PubMed: 30410599 ( click the link to review the publication )

Kidney Blood Press Res, 2018, 43(2):616-627

PubMed: 29689548 ( click the link to review the publication )

Biochem Pharmacol, 2018, 156:22-31

PubMed: 30077642 ( click the link to review the publication )

Toxicol Lett, 2018, 296:125-131

PubMed: 30121340 ( click the link to review the publication )

Br J Cancer, 2018, 118(6):e13

PubMed: 29438360 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )

Gut, 2017, 66(8):1358-1368

PubMed: 27196599 ( click the link to review the publication )

Mol Cell, 2017, 68(1):185-197

PubMed: 28943315 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9441-9454

PubMed: 28934491 ( click the link to review the publication )

Dev Cell, 2017, 41(3):274-286

PubMed: 28457793 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

Cancer Res, 2017, 77(23):6614-6626

PubMed: 28951465 ( click the link to review the publication )

Haematologica, 2017, 102(5):826-834

PubMed: 28154085 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Oncogene, 2017, 36(26):3781-3788

PubMed: 28192398 ( click the link to review the publication )

Front Cell Neurosci, 2017, 11:281

PubMed: 29033786 ( click the link to review the publication )
Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0181601

PubMed: 28806746 ( click the link to review the publication )

Cell Biochem Biophys, 2017, 75(1):119-129

PubMed: 27990613 ( click the link to review the publication )

Exp Ther Med, 2017, 13(5):2169-2176

PubMed: 28565824 ( click the link to review the publication )

PPAR Res, 2017, 2017:4313561

PubMed: 29056962 ( click the link to review the publication )

Neuroscience, 2017, 351:24-35

PubMed: 28359951 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Sci Rep, 2017, 7:43517

PubMed: 28262781 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.247

PubMed: 27399335 ( click the link to review the publication )

Cell Death Dis, 2016, 7(11):e2459

PubMed: 27831567 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1332-43

PubMed: 27196784 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

Cell Cycle, 2016, 15(20):2742-52

PubMed: 27580187 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1083-90

PubMed: 27279017 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34785-99

PubMed: 27166183 ( click the link to review the publication )

Dev Cell, 2015, 33(6):703-16

PubMed: 26051540 ( click the link to review the publication )

Oncogene, 2015, 34(34):4460-70

PubMed: 25399696 ( click the link to review the publication )

Nucleic Acids Res, 2015, 43(20):9788-803

PubMed: 26275776 ( click the link to review the publication )

Nat Commun, 2014, 5:5637

PubMed: 25472497 ( click the link to review the publication )

J Hematol Oncol, 2014, 7(1):53

PubMed: 25084614 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

J Cell Biol, 2013, 201(7):997-1012

PubMed: 23775190 ( click the link to review the publication )
Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Mol Pharm, 2013, 10(12):4620-8

PubMed: 24168213 ( click the link to review the publication )

J Biol Chem, 2013, 288(36):25924-37

PubMed: 23888052 ( click the link to review the publication )

Cell Cycle, 2013, 12(23):3689-701

PubMed: 24189531 ( click the link to review the publication )

Circ Res, 2012, 111(2):201-11

PubMed: 22652908 ( click the link to review the publication )

J Neurosci, 2012, 32(32):11050-66

PubMed: 22875938 ( click the link to review the publication )

Br J Cancer, 2012, 106(3):482-9

PubMed: 22233925 ( click the link to review the publication )

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述

靶点

CDK5/p35 ^[1] (Cell-free assay)	Cdc2/CyclinB ^[1] (Cell-free assay)	CDK2/CyclinA ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	ERK2 ^[1] (Cell-free assay)
0.16 μM	0.65 μM	0.7 μM	0.7 μM	14 μM

体外研究

Roscovitine作用于细胞周期蛋白依赖性激酶具有高效性和高度选择性，作用于cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E和cdk5/p53时IC50分别为0.65,0.7,0.7和0.16 μM。纳摩尔级Roscovitine作用于海星卵母细胞和海胆胚胎，可逆抑制在前中期间转变, 在体外作用于非洲爪蟾卵提取物，抑制M期促进因子活性和体外DNA合成,且抑制哺乳动物细胞系增殖，IC50为16 μM。^[1] 浓度为7.5, 12.5和 25 mM的 Roscovitine作用于肾小球系膜细胞,导致CDK2活性分别降低25,50% 和100%，这种作用存在剂量依赖性。^[2] 最新研究显示Roscovitine作用于盘基网柄菌，抑制cdk5激酶活性,细胞增殖,多细胞发展,和cdk5核转运, 不会影响cdk5蛋白表达。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
LB771-HNC	NU[2U3BPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlLmTWM2OD12OD65NlEzKM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
LB2241-RCC	NGjsWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUjJR\|UxRTR6Lk[yNFIh\|ryP	MnLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
DU-4475	NIq3[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHPlPYNKSzVyPUS4MlQ6OzdizszN	NYXSeo91RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
LB2518-MEL	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkD2TWM2OD12Nz6wOFQ5KM7:TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
NCI-H209	NYnsSVVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFnqXHZKSzVyPUS2MlAyOTVizszN	M{X6PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
CGTH-W-1	M4PSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV3JR\|UxRTR2Lkm2PVch\|ryP	NIWxOJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
MS-1	MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkfJTWM2OD12Mj64PVMh\|ryP	M4rkTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
GI-ME-N	NIDOd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWi2cJlFUUN3ME20Nk43PjdzIN88US=>	Mn\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
DG-75	M3LxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml\ITWM2OD12Mj62OVQ3KM7:TR?=	M{\Kd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
MLMA	NGfjUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYnJR\|UxRTR{LkK3PFch\|ryP	NYjMcHF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
HT	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3noOmlEPTB;NEKuNFAzQCEQvF2=	NWHRXYZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
LC-1F	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVnJR\|UxRTRzLkW3NFUh\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
NCI-H1882	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV;JR\|UxRTRyLkW5PVgh\|ryP	NGrqbm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
NTERA-S-cl-D1	M4mx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXPJR\|UxRTN7LkW4OFIh\|ryP	MoSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
NCI-H345	MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4TSfWlEPTB;M{iuPVExPiEQvF2=	MlzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
MONO-MAC-6	MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGXBS\|lKSzVyPUO4MlI1PzdizszN	NF\TNWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
RS4-11	MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEf1b5ZKSzVyPUO3MlcxPjlizszN	MkL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
ML-2	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4TpbWlEPTB;M{euOlcyOiEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
OPM-2	NXLq[nk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWTJR\|UxRTN5LkK5OFkh\|ryP	MoTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
LU-139	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmPJTWM2OD1\|Nz6xPFU3KM7:TR?=	NUXzOGZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
COLO-684	M{ewSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWnJR\|UxRTN5LkCxNkDPxE1?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
MOLT-4	NFLqeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkLkTWM2OD1\|Nj6zNlc3KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
TE-6	NHX4SIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXnJR\|UxRTN4LkOyOFYh\|ryP	MoLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
TE-441-T	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGjxcGVKSzVyPUO2MlEyPDhizszN	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
IMR-5	NHrKUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4qzfGlEPTB;M{WuN\|E{QSEQvF2=	MonwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
K5	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MX3JR\|UxRTN3LkC4OlEh\|ryP	NXm4UmRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
TE-10	NEfze4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXPXcmFTUUN3ME2zOE46PDJ{IN88US=>	NGnO[3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
NCI-H2141	M2fn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGSycY1KSzVyPUO0MlY2OzNizszN	M1fFTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
KGN	M4PXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn3iTWM2OD1\|ND6yOVI1KM7:TR?=	NFrK[Gg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
LP-1	M3TFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2fhPWlEPTB;M{OuPFkxQCEQvF2=	NEPzfGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
NCI-H64	M33YZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlOwTWM2OD1\|Mz64OVk4KM7:TR?=	NYDmS\|dqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
RKO	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M13S[WlEPTB;M{OuOVk3QSEQvF2=	MlzYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
NCI-H526	NFLWNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXTJR\|UxRTN\|LkS5N\|Yh\|ryP	NUXzOWVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
GOTO	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoKyTWM2OD1\|Mj65NVI6KM7:TR?=	Ml\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
Calu-6	M3exV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVTJR\|UxRTN{LkS3OFUh\|ryP	NUT3epg1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
LOUCY	M4nFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHHPe5hKSzVyPUOyMlEzPTNizszN	NVLiWWxURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
SK-N-FI	MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHTreWZKSzVyPUOxMlc2OzVizszN	NWfldm1ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
SIG-M5	NVrwVlZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXWybGF1UUN3ME2zNU43QDN\|IN88US=>	NVfxNo1MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
NKM-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVLJR\|UxRTNzLkGzPVch\|ryP	M4TjS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1	NELV[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1naSGlEPTB;M{GuNVA2QSEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
NCI-H82	NVzGWWQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1zuUmlEPTB;M{GuNFE{PSEQvF2=	NHnMXmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
NCI-H510A	NWGxWJF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVTJR\|UxRTNyLkCzNlkh\|ryP	NX3KT4FGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
ES3	NVLKcow5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoDuTWM2OD1{OT65OVgzKM7:TR?=	NEn1eWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
BB30-HNC	M4mwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NI\BflRKSzVyPUK5Mlk1QDNizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
KM12	M175Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3[yT2lEPTB;MkmuOlI{QSEQvF2=	NIqwPY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
GI-1	NH\hW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MV;JR\|UxRTJ7LkCxNVMh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
NOS-1	MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYPhdYJNUUN3ME2yPE46PzN\|IN88US=>	MmK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
TE-8	NYrlO5ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYPTNo5sUUN3ME2yPE46ODhizszN	NELFWFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
TE-9	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4[4[mlEPTB;MkiuO\|k3QSEQvF2=	NXXOdGNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
HL-60	M3vOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXLKWGVYUUN3ME2yO{46QDZ7IN88US=>	NUXwdVI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
QIMR-WIL	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1\zd2lEPTB;MkeuPVE1PCEQvF2=	M1jTUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
KARPAS-299	M3P2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4PlUmlEPTB;Mk[uPFY1PiEQvF2=	MlTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
KURAMOCHI	M1:2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEHMcm5KSzVyPUK2MlgxQDJizszN	NGDNSYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
BL-41	M2TyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWe1O\|JRUUN3ME2yOU46PTl5IN88US=>	NEHWXI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
NCI-H2126	NGTadGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGLWU3pKSzVyPUK1MlY2OjlizszN	NIjLWFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
HOP-62	NVmzfo97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVmyblZnUUN3ME2yOU41PDJ3IN88US=>	M2\0T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
IST-SL2	NH\ZO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYX0eFlvUUN3ME2yOE42OzR\|IN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
HH	NYjaNVhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnrCTWM2OD1{ND6zPFE6KM7:TR?=	NW\YemhURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
LS-513	Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUnkR5F{UUN3ME2yN{42OTd7IN88US=>	NVPvVnRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
EB-3	NXTuVWhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUfJR\|UxRTJ\|LkG4N\|Eh\|ryP	MojsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
ACN	MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUjJR\|UxRTJzLkOzPFkh\|ryP	NIO2e5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
NOMO-1	NGLU[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWn6NHRYUUN3ME2yNU4zODB6IN88US=>	NHv0fY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
ES8	MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUf2[GhtUUN3ME2yNU4xPiEQvF2=	NHvve3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
CESS	NH;sO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MX7JR\|UxRTJyLki1OFkh\|ryP	MkXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
BL-70	MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHvMe4dKSzVyPUKwMlMzPzRizszN	NULEO4VuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
MHH-PREB-1	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFzDb3dKSzVyPUKwMlA{PTZizszN	NUDufHJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
BC-1	NIK2VIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{Ly[WlEPTB;MUmuNVE6QCEQvF2=	MmLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
LC4-1	MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml\ZTWM2OD1zOD64O\|M1KM7:TR?=	M32xdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
COLO-320-HSR	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmWzTWM2OD1zOD63Olg5KM7:TR?=	NWX6UGZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
A101D	M1LjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX\2U\|A4UUN3ME2xPE4{OjB6IN88US=>	NHLkd2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
BC-3	NXu1NnRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlHzTWM2OD1zOD6wN\|A2KM7:TR?=	MorHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
TGW	NHnrXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYDHe5FmUUN3ME2xO{45OTJ2IN88US=>	NFXuOGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
JAR	NED0WFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIfTSJNKSzVyPUG3MlAyPTJizszN	NIXSXIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
HD-MY-Z	M4WzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnfsTWM2OD1zNj64NlQ3KM7:TR?=	M2\0U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
NCI-H1304	M4rwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFfvXm5KSzVyPUG2MlM3ODFizszN	NIKxUYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
OS-RC-2	NYT2[JFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmOwTWM2OD1zNT64N\|gzKM7:TR?=	NUjPUZhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
OCI-AML2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF76NnVKSzVyPUG1MlY1QDJizszN	NYPvfndRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
HCC1599	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mm\0TWM2OD1zND61PVc2KM7:TR?=	MnLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
SCC-3	NX3vOXVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXTJR\|UxRTF2LkK5OVYh\|ryP	NYXj[4FDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
RPMI-6666	NH\QZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFjLOGpKSzVyPUGzMlkyOjFizszN	M175SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
MEG-01	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVfJR\|UxRTF\|LkizO\|kh\|ryP	Mk\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
Raji	MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mn7NTWM2OD1zMz63PFk1KM7:TR?=	NG\LbZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
RPMI-8402	MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoPTTWM2OD1zMz62NlYzKM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
GCIY	M17XW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnvKTWM2OD1zMj64OlE{KM7:TR?=	NUDkbmhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
697	NVLoTlBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWeyfWhCUUN3ME2xNk43ODB5IN88US=>	Mkm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
D-247MG	M4rLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{TFXWlEPTB;MUKuN\|UyPiEQvF2=	NVn1eFZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
NB1	M4POSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnHDTWM2OD1zMj6zN\|A5KM7:TR?=	MmjrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
COR-L279	NVzMN20{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEHXSHJKSzVyPUGyMlI6ODdizszN	NUnQ[JhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
LB831-BLC	MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGDhXI5KSzVyPUGxMlU3OjRizszN	MmPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
ST486	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYPUT49wUUN3ME2xNE4{PTFizszN	NVLwZoRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
SK-UT-1	NX;tXJM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIPXN5BKSzVyPUGwMlM2KM7:TR?=	NYXCVIZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
BB65-RCC	MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlHZTWM2OD17Lkm3OFk2KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFc3Oi9pPmPBUmdGWjxxYU6=
KARPAS-422	NG\SU\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWLJR\|UxRTlwOU[zN\|Yh\|ryP	NXjCXlMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
Becker	NFP6ZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUPJR\|UxRTlwNE[wPFIh\|ryP	NITiSW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
KS-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mm\ZTWM2OD17LkS1O\|g2KM7:TR?=	M4P6ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
JiyoyeP-2003	NWO5Z4JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3i1UWlEPTB;OD61NFI3PCEQvF2=	Mn;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ4PjJxJ{7TRW5ITVJ:L3G+
NCCIT	NFP0U4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUPJR\|UxRTdwNUW0PFIh\|ryP	NVLoNnlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR5NkKvK\|5USU6JRWK8M4E,
MRK-nu-1	M2m1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmHhTWM2OD15LkGyPVY6KM7:TR?=	NEf4d4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDd4Mj:nQnNCVkeHUkyvZV4>
A3-KAW	NULZ[INtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWX2OlZNUUN3ME21Mlc3OTF4IN88US=>	M3;Hc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1PzZ{Lze+V2FPT0WUPD;hQi=>
SK-N-MC	MkXVdWhVWyCjc4PhfS=>			NF;rfVhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	MnPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV7NUi1PFkoRjF3OUW4OVg6RC:jPh?=
LP-1	MlvCRZBweHSxc3nzJIF{e2G7	MVyzNEB2VQ>?	M1jGU\|MhcHK\|	NXj1U5VSUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDMVE0yKGOnbHzzJIF1KDNyIIXNJIFnfGW{IEOgbJJ{KHW\|aX7nJHRWVkWOIIP0ZYlvcW6pIHL5JIZtd3diY4n0c41mfHK7	NVnY[2tCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW5OVg2QDlpPkG1PVU5PTh7PD;hQi=>
LP-1	NXyzSWloS3m2b4TvfIlkcXS7IHHzd4F6	NX3TUolMOjBidH:gN\|AhfU1?	MXWyOEBpenN?	NEf1e5REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNWC1zIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDheEAzOCC2bzCzNEB2VSC2cnXheIVlKG[xcjCyOEBpenNiZn;scI94\WRiYomge4F{cG:3dDDt[YF{fXKnZDDh[pRmeiC2b4ThcEA4OiCqcoOg[5Jwf3SqIIDldolw\CCjbHHtZZIh[my3ZTDhd5NigSC{ZXzheIl3\SC2bzDjc451em:u	NITnTVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUm1PFU5QSd-MUW5OVg2QDl:L3G+
LP-1	NUDV[ZJzSXCxcITvd4l{KGG\|c3H5	Mo\QN\|AhfU1?	NFTRc20yNjViaILz	MkW5TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCOUD2xJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCUTlGgdI9tgW2ncnHz[UAzKHCqb4PwbI9{\XKrbnWgNkBt\X[nbDDheEA{OCC3TTDh[pRmeiBzLkWgbJJ{KGK7IHntcZVvd2Kub4T0bY5o	NFvkW2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUm1PFU5QSd-MUW5OVg2QDl:L3G+
LP-1	NX7NS25CSXCxcITvd4l{KGG\|c3H5	NULoSm5ROzBidV2=	M4jqXVMhcHK\|	NGXhdolKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFzQMVEh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIF3jcE0yKHC{b4TlbY4hdGW4ZXygZZQhOzBidV2gZYZ1\XJiMzDodpMh[nliaX3teY5w[myxdITpcoc>	NYG2bFNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW5OVg2QDlpPkG1PVU5PTh7PD;hQi=>
LP-1	MYTBdI9xfG:\|aYOgZZN{[Xl?	MnLQN\|AhfU1?	M2\4dFMhfG9iNTDodpM>	M1jSe2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTGCtNUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCuZY\lcEBw\iClbHXheoVlKFCDUmCgZZQhOzBidV2gZYZ1\XJiMzD0c{A2KGi{czDifUBqdW23bn;icI91fGmwZx?=	NUjh[WZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW5OVg2QDlpPkG1PVU5PTh7PD;hQi=>
NCI-H929	M4jrR2Fxd3C2b4Ppd{Bie3OjeR?=	MXizNEB2VQ>?	MY[1JIhzew>?	NGXsPVJKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF7DTU1JQTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIxmfmWuIH;mJINt\WG4ZXSgVGFTWCCjdDCzNEB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91fGmwZx?=	M4Sxc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OUW4OVg6Lz5zNUm1PFU5QTxxYU6=
NCI-H929	NVnNTGlZSXCxcITvd4l{KGG\|c3H5	M3H6UFMxKHWP	NIPqeI8yNjViaILz	MU\JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE6FST3IPVI6KGOnbHzzJIF{e2W\|c3XkJIF{KG[jc4Sgd4xwfyCvaXfyZZRqdmdiaInw[ZJxcG:\|cHjvdplt[XSnZDDSUmEheG:ueX3ldoF{\SB{TzDmc5JuKGG2IEOwJJVOKGGodHXyJFEvPSCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTl3OEW4PUc,OTV7NUi1PFk9N2F-
RPM18226	M17aXmFxd3C2b4Ppd{Bie3OjeR?=	NIXEVFI{OCC3TR?=	MXexMlUhcHK\|	NX\xWoxsUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDSVG0yQDJ{NjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhWk6DIIDvcJlu\XKjc3WgNkBxcG:\|cHjvd4VzcW6nIEKgcIV3\WxiYYSgN\|AhfU1iYX\0[ZIhOS53IHjyd{BjgSCrbX31co9jdG:2dHnu[y=>	NG\wSlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUm1PFU5QSd-MUW5OVg2QDl:L3G+
RPM18226	M4[4PGFxd3C2b4Ppd{Bie3OjeR?=	MnTqN\|AhfU1?	MYmzJIhzew>?	M13GSWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iUmDNNVgzOjZiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJG1kdC1zIIDyc5RmcW5ibHX2[Ywh[XRiM{CgeW0h[W[2ZYKgN{BpenNiYomgbY1ufW6xYnzveJRqdmd?	M3XmSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OUW4OVg6Lz5zNUm1PFU5QTxxYU6=
RPM18226	MmTHRZBweHSxc3nzJIF{e2G7	M1HiUFMxKHWP	Mon1N{B1dyB3IHjydy=>	NFfwUJVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGLQUVE5OjJ4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIxmfmWuIH;mJINt\WG4ZXSgVGFTWCCjdDCzNEB2VSCjZoTldkA{KHSxIEWgbJJ{KGK7IHntcZVvd2Kub4T0bY5o	M4rGd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OUW4OVg6Lz5zNUm1PFU5QTxxYU6=
NCI-H929	NU\R[FlxSXCxcITvd4l{KGG\|c3H5	M3GyPFMxKHWP	MV2zJIhzew>?	NED5bHJKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF7DTU1JQTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPoZY5o\XNiaX6gXGlCWCCycn;0[YlvKGyndnXsJIF1KDNyIIXNJIFnfGW{IEOgbJJ{KGK7IHntcZVvd2Kub4T0bY5o	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTl3OEW4PUc,OTV7NUi1PFk9N2F-
NCI-H929	M1nFPWFxd3C2b4Ppd{Bie3OjeR?=	Ml;4N\|AhfU1?	NGi5e\|g{KGi{cx?=	NXHx[IlqUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDOR2kuUDl{OTDj[YxteyCjc4Pld5Nm\CCjczDjbIFv\2W\|IHnuJJN2en[rdnnuJJBzd3SnaX6gcIV3\WxiYYSgN\|AhfU1iYX\0[ZIhOyCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTl3OEW4PUc,OTV7NUi1PFk9N2F-
RPM18226	NFu1eJZCeG:ydH;zbZMh[XO\|YYm=	NEOzZY0{OCC3TR?=	MUCzJIhzew>?	M3zPR2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iUmDNNVgzOjZiY3XscJMh[XRiM{CgeW0h[W[2ZYKgN{BpenNidYPpcochXFWQRVygd5RicW6rbnegZpkh\myxdzDjfZRwdWW2com=	NWnqZpVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW5OVg2QDlpPkG1PVU5PTh7PD;hQi=>
NCI-H929	MojzRZBweHSxc3nzJIF{e2G7	MlH5N\|AhfU1?	MV[xMlUhcHK\|	NVn3RlR2UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDOR2kuUDl{OTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhWk6DIIDvcJlu\XKjc3WgNkBxcG:\|cHjvd4VzcW6nIEKgcIV3\WxiYYSgN\|AhfU1iYX\0[ZIhOS53IHjyd{BjgSCrbX31co9jdG:2dHnu[y=>	NV7ZdWZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW5OVg2QDlpPkG1PVU5PTh7PD;hQi=>
NCI-H929	MUXBdI9xfG:\|aYOgZZN{[Xl?	MnTWN\|AhfU1?	M2q2Z\|EvPSCqcoO=	NHnWTXZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF7DTU1JQTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTldIhwe3Cqb4L5cIF1cW:wIH;mJJBT[iCjdDDTNlQ6N1R{NUKgZZQhOzBidV2gZYZ1\XJiMT61JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>?	MlnIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV7NUi1PFkoRjF3OUW4OVg6RC:jPh?=
NCI-H929	MVPDfZRwfG:6aXPpeJkh[XO\|YYm=	NHTaU2MzOCC2bzCzNEB2VQ>?	NH20TYYyPiCqcoO=	MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDl{OTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yh[2WubDD2bYFjcWyrdImgZZQhOjBidH:gN\|AhfU1idILlZZRm\CCob4KgNVYhcHK\|IH\vcIxwf2WmIHL5JJdie2ixdYSgcYVie3W{ZXSgZYZ1\XJidH;0ZYwhPzJiaILzJIdzd3e2aDDw[ZJqd2RiYXzhcYFzKGKudXWgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbB?=	NGDFcpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUm1PFU5QSd-MUW5OVg2QDl:L3G+
NCI-H929	NF3qZmlCeG:ydH;zbZMh[XO\|YYm=	M33vSFMxKHWP	NIfUSHo{KGi{cx?=	M4Lob2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTlPJMWg6OjliY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJG1kdC1zIIDyc5RmcW5ibHX2[Ywh[XRiM{CgeW0h[W[2ZYKgN{BpenNiYomgbY1ufW6xYnzveJRqdmd?	NFjnTG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUm1PFU5QSd-MUW5OVg2QDl:L3G+
NCI-H929	M1znWGFxd3C2b4Ppd{Bie3OjeR?=	NVrMW4cyOzBidV2=	MX[zJIhzew>?	Mn6wTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCQQ1mtTFkzQSClZXzsd{Bie3Onc4Pl[EBieyClaHHu[4V{KGmwIFLjcE0zKHC{b4TlbY4hdGW4ZXygZZQhOzBidV2gZYZ1\XJiMzDodpMh[nliaX3teY5w[myxdITpcoc>	M2nsU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OUW4OVg6Lz5zNUm1PFU5QTxxYU6=
NCI-H929	M3ThNmFxd3C2b4Ppd{Bie3OjeR?=	NXLKbJJMOzBidV2=	MnPWN{BpenN?	NVTje4loUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDOR2kuUDl{OTDj[YxteyCjdDCzNEB2VSCjZoTldkA{KGi{czD1d4lv\yCWVV7FUEB{fGGrbnnu[{BjgSCobH;3JIN6fG:vZYTyfS=>	NFv1PJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUm1PFU5QSd-MUW5OVg2QDl:L3G+
NCI-H929	NE\Od\|hCeG:ydH;zbZMh[XO\|YYm=	MnTHN\|AhfU1?	NIDEbFEyNjViaILz	M2C3UWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTlPJMWg6OjliY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHJPSSCyb3z5cYVz[XOnIEKgdIhwe3Cqb4Pldolv\SB3IHzleoVtKGG2IEOwJJVOKGGodHXyJFEvPSCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	M1nDPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OUW4OVg6Lz5zNUm1PFU5QTxxYU6=
NCI-H929	MXTBdI9xfG:\|aYOgZZN{[Xl?	MVuzNEB2VQ>?	MXexMlUhcHK\|	NEmzemhKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF7DTU1JQTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDv[kBJ\G1{IHzleoVtKGG2IEOwJJVOKGGodHXyJFEvPSCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	NITqfnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUm1PFU5QSd-MUW5OVg2QDl:L3G+
NCI-H929	M1;n[GFxd3C2b4Ppd{Bie3OjeR?=	M1vQO\|MxKHWP	M{X3TFEvPSCqcoO=	MYfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE6FST3IPVI6KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKG:oIIC1N{Bi[2O3bYXsZZRqd25iYYSgN\|AhfU1iYX\0[ZIhOS53IHjyd{BjgSCrbX31co9jdG:2dHnu[y=>	MnzEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV7NUi1PFkoRjF3OUW4OVg6RC:jPh?=
SK-N-MC	MVzxTHRUKGG\|c3H5			MnzEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	M3ruRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEiwO\|A{Lz5{MUC4NFcxOzxxYU6=
HCT116	NWX1dnJ6TnWwY4Tpc44h[XO\|YYm=	M3\6WlMxKHSxIESwJJVud2xxTB?=	M3i3ZVI1KGi{cx?=	NF7TZ\|FKdmirYnn0bY9vKG:oIHP5Z4xqdiCDIHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDwdo91\WmwIHzleoVtKGG2IEOwJJRwKDRyIIXtc4wwVCCjZoTldkAzPCCqcoOgZpkhcW2vdX7vZoxwfHSrbnegZY5idHm\|aYO=	NEW1TlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFcxOyd-MkGwPFA4ODN:L3G+
HCT116	MVrGeY5kfGmxbjDhd5NigQ>?	NGTIPY8{OCC2bzC0NEB2dW:uL1y=	NGDCeIEzPCCqcoO=	MUPJcohq[mm2aX;uJI9nKGO7Y3zpckBDKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCycn;0[YlvKGyndnXsJIF1KDNyIITvJFQxKHWvb3yvUEBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmdiYX7hcJl{cXN?	NW\T[HZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPFA4ODNpPkKxNFgxPzB\|PD;hQi=>
HCT116	M{XRU2Z2dmO2aX;uJIF{e2G7	M3P0RlMxKHSxIESwJJVud2xxTB?=	Mm\FNlQhcHK\|	MnXyTY5pcWKrdHnvckBw\iCleXPsbY4hTDFiaX6gbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIIDyc5RmcW5ibHX2[Ywh[XRiM{CgeI8hPDBidX3vcE9NKGGodHXyJFI1KGi{czDifUBqdW23bn;icI91fGmwZzDhcoFtgXOrcx?=	NGL5b4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFcxOyd-MkGwPFA4ODN:L3G+
HCT116	NGLqN41HfW6ldHnvckBie3OjeR?=	MXizNEB1dyB2MDD1cY9tN0x?	NHj5XpUzPCCqcoO=	MmP6TY5pcWKrdHnvckBw\iCFRFuyJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBxem:2ZXnuJIxmfmWuIHH0JFMxKHSxIESwJJVud2xxTDDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdITpcoch[W6jbInzbZM>	M3Tw[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEiwO\|A{Lz5{MUC4NFcxOzxxYU6=
HT-29	NGX2U\|BHfW6ldHnvckBie3OjeR?=	NUDW[YVpOi53IITvJFQxKHWP	MVSyOEBpenN?	NEXYRnBKdmirYnn0bY9vKG:oIILleIlvd2KuYYP0c41iKHC{b4TlbY4hcW5iaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKGO7Y3zpckBCKGyndnXsJIF1KDJwNTD0c{A1OCC3TTDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdITpcoc>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTRzN{SxO{c,OjF2MUe0NVc9N2F-
MCF7	MkfjR4VtdCCleXPs[UBie3OjeR?=		MX6yOEBpenN?	MkWzR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzJxTTDwbIF{\SCjZoTldkAzPCCqcoOgeZNqdmdicILvdIllcXWvIHnv[Ill\SCjbnSgRpJlXSC\|dHHpcolv\yCkeTDmcI94KGO7dH;t[ZRzgQ>?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTRzN{SxO{c,OjF2MUe0NVc9N2F-
RPMI8226	NULSPHFGS2WubDDjfYNt\SCjc4PhfS=>		NIXTWIkzPCCqcoO=	MWrD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDSVG1KQDJ{NjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG\|ZTDh[pRmeiB{NDDodpMhfXOrbnegdJJweGmmaYXtJIlw\GmmZTDhcoQhSnKmVTDzeIFqdmmwZzDifUBndG:5IHP5eI9u\XS{eR?=	NUfHSnlLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0NVc1OTdpPkKxOFE4PDF5PD;hQi=>
MCF7	MWDD[YxtKGO7Y3zlJIF{e2G7		MofZNlQhcHK\|	Mn7yR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDTJJBp[XOnIHPlcIwheG:ydXzheIlwdiCjZoTldkAzPCCqcoOgeZNqdmdicILvdIllcXWvIHnv[Ill\SCjbnSgRpJlXSC\|dHHpcolv\yCkeTDmcI94KGO7dH;t[ZRzgQ>?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTRzN{SxO{c,OjF2MUe0NVc9N2F-
MCF7	MV\D[YxtKGO7Y3zlJIF{e2G7		M1TaSFI1KGi{cx?=	NW\qTHVqS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRic4XiMWcyKHCqYYPlJIFnfGW{IEK0JIhzeyC3c3nu[{Bxem:yaXTpeY0hcW:maXTlJIFv\CCEcnTVJJN1[WmwaX7nJIJ6KG[ub4egZ5l1d22ndIL5	M2XVTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEG3OFE4Lz5{MUSxO\|QyPzxxYU6=
RPMI8226	MVTD[YxtKGO7Y3zlJIF{e2G7		NGnJcZozPCCqcoO=	Moq1R4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gVnBOUTh{Mk[gZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[UBi\nSncjCyOEBpenNidYPpcocheHKxcHnkbZVuKGmxZHnk[UBidmRiQoLkWUB{fGGrbnnu[{BjgSCobH;3JIN6fG:vZYTyfS=>	M4PETFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEG3OFE4Lz5{MUSxO\|QyPzxxYU6=
MCF7	MX;D[YxtKGO7Y3zlJIF{e2G7	NGTvOmw5OCC3TR?=	Mkn0NlQhcHK\|	MXzD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjDhZ5RqfmWueTDy[ZBtcWOjdHnu[{BFVkFibHX2[Ywh[XRiOECgeW0h[W[2ZYKgNlQhcHK\|IIXzbY5oKHC{b4Dp[Il2dSCrb3Tp[IUh[W6mIFLy[HUhe3SjaX7pcoch[nliZnzve{BkgXSxbXX0dpk>	MlnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2MUe0NVcoRjJzNEG3OFE4RC:jPh?=
MCF7	NEnJT4ZHfW6ldHnvckBie3OjeR?=	M1v1[FIxKHWP	MY[yOEBpenN?	M3fTOWlv\HWldHnvckBw\iCyNUOt[IVx\W6mZX70JJRz[W6\|Y4LpdJRqd26jbDDhZ5Rqfmm2eTDpckBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKG:oIICyNUBYSUZzIHzleoVtKGG2IEKwJJVOKGGodHXyJFI1KGi{czDifUBqdW23bn;mcJVwemW\|Y3XuZ4Uh[XO\|YYm=	NYnhUYxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0NVc1OTdpPkKxOFE4PDF5PD;hQi=>
RPMI8226	MUXD[YxtKGO7Y3zlJIF{e2G7		MnH1NlQhcHK\|	MlrVR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gVnBOUTh{Mk[gZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hWyCyaHHz[UBk\WyuIIDvdJVt[XSrb36gZYZ1\XJiMkSgbJJ{KHW\|aX7nJJBzd3CrZHn1cUBqd2SrZHWgZY5lKEK{ZGWgd5RicW6rbnegZpkh\myxdzDjfZRwdWW2com=	NV;PTpdLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0NVc1OTdpPkKxOFE4PDF5PD;hQi=>
RPMI8226	M4[5OGNmdGxiY4njcIUh[XO\|YYm=	NGK2dFU5OCC3TR?=	NGnZS48zPCCqcoO=	NYWzSXVmS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hWlCPSUiyNlYh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIHHjeIl3\Wy7IILldIxq[2G2aX7nJGRPSSCuZY\lcEBifCB6MDD1UUBi\nSncjCyOEBpenNidYPpcocheHKxcHnkbZVuKGmxZHnk[UBidmRiQoLkWUB{fGGrbnnu[{BjgSCobH;3JIN6fG:vZYTyfS=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTRzN{SxO{c,OjF2MUe0NVc9N2F-
A549	MlH6RZBweHSxc3nzJIF{e2G7	MWmyJJVO	M1rKdlQ5KGi{cx?=	M2DpZWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BFVkFiZoLh[41mdnSjdHnvckBifCB{IIXNJIFnfGW{IES4JIhzeyCkeTDh[4Fzd3OnIHflcEBmdGWldILvdIhwemW\|aYO=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ{M{S5NUc,OjN4MkO0PVE9N2F-
Sf9	MVzGeY5kfGmxbjDhd5NigQ>?		M{TKXlExKG2rboO=	M3jDd2lvcGmkaYTpc44hd2ZiSHnzMVYufGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJGNFUzJxY4njcIlvTSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMucW6oZXP0[YQhe2Z7IHPlcIx{KHW\|aX7nJIhqe3SxbnWgTFEh[XNic4Xid5Rz[XSnIHHmeIVzKDFyIH3pcpMh[nlibHnxeYllKHOlaX70bYxt[XSrb36gZ492dnSrbnegbY4heHKnc3XuZ4Uhd2ZiW3fhcY1iNTN{UG3BWHAtKEmFNUCgQUAxNjFizszNMi=>	M{LrclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEG3OVY3Lz5{NESxO\|U3PjxxYU6=
BJ	MUfGeY5kfGmxbjDhd5NigQ>?	NHLtcGIyOCC3TR?=	NFi0XVIyOCCmYYnz	NXnoSHhwW3WycILld5Nqd25ib3[gd4Vv\XOlZX7j[UBqdiCqdX3hckBDUiClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDj[YxtKG63bXLldkBifCBzMDD1UUBi\nSncjCxNEBl[Xm\|IHL5JJNmdmW\|Y3XuZ4UhemW4ZYLzZYwh[XO\|YYm=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6MUm4Okc,OjR4OEG5PFY9N2F-
BJ	NF3mS2NHfW6ldHnvckBie3OjeR?=	NXHDW\|lrOTBidV2=	NGTMfY8yOCCmYYnz	M2jWXGlvcGmkaYTpc44hd2ZiYYThfIliKHSnbHHu[4lm[3Sjc3nhMY12fGG2ZXSgbY4hcHWvYX6gRmoh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iY3XscEBvfW2kZYKgZZQhOTBidV2gZYZ1\XJiMUCg[IF6eyCkeTDz[Y5me2OnbnPlJJJmfmW{c3HsJIF{e2G7	MlzmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEG5PFYoRjJ2NkixPVg3RC:jPh?=
MCF7	MlzpSpVv[3Srb36gZZN{[Xl?	NEPyeFAyOCC3TR?=	MlTwNVAhdWmwcx?=	M{jzT3NmdnOrdHn6ZZRqd25ib3[gbY5nemG{ZXStbY5lfWOnZDDEUmEh\GGvYXflJIlvKGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINwdG:weTDmc5Ju[XSrb36gZZQhOTBidV2gdJJmfHKnYYTl[EBnd3JiMUCgcYlveyCob3zsc5dm\CCkeTDpdpJi\GmjdHnvckBnd3JiNDDodpMhdWWjc4Xy[YQh[W[2ZYKgNVAh\GG7czDifUBkenm\|dHHsJJZqd2yndDDzeIFqdmmwZzDhcoFtgXOrcx?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh3MUWwOUc,OjZ6NUG1NFU9N2F-
Caco2	NVXRO3BnS2WubDDjfYNt\SCjc4PhfS=>			M1zwS2NmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGNi[29{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMT;TJJBp[XOnIHL5JGhw\WOqc4Sgd5RicW6rbnegZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7	M{DoSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkG0NlMyLz5{OEKxOFI{OTxxYU6=
HaCaT	M{\MWGNmdGxiY4njcIUh[XO\|YYm=			NIjqOHdE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBJ[UOjVDDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GvV{BxcGG\|ZTDifUBJd2WlaIP0JJN1[WmwaX7nJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?=	M13lOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkG0NlMyLz5{OEKxOFI{OTxxYU6=
HuH7	NIjyc5hE\WyuIHP5Z4xmKGG\|c3H5			M1jRNmNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGh2UDdiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzL2OgdIhie2ViYomgTI9m[2i\|dDDzeIFqdmmwZzDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJzNEKzNUc,Ojh{MUSyN\|E9N2F-
PC3	NWfIUIlNS2WubDDjfYNt\SCjc4PhfS=>			NF\O[FNE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBRSzNiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2ViYomgTI9m[2i\|dDDzeIFqdmmwZzDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl?	NVHYd5hLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNVQzOzFpPkK4NlE1OjNzPD;hQi=>
MDA-MB-231	MmPSR4VtdCCleXPs[UBie3OjeR?=			NWfVNo5WS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFxUzDwbIF{\SCkeTDIc4VkcHO2IIP0ZYlvcW6pIHLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigQ>?	NYXxfXZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNVQzOzFpPkK4NlE1OjNzPD;hQi=>
HCT116	NGjpbllE\WyuIHP5Z4xmKGG\|c3H5			NEn6U4dE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFexM3MheGijc3WgZpkhUG:nY3jzeEB{fGGrbnnu[{Bj[XOnZDDmcJVwemW\|Y3XuZ4Uh[XO\|YYm=	NFH5b5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKxOFI{OSd-MkiyNVQzOzF:L3G+
SK-N-MC	MX;xTHRUKGG\|c3H5			MnfPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	NFKxTpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O\|Q{OCd-Mki1OVc1OzB:L3G+
A673	MYjxTHRUKGG\|c3H5			MoXsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	Mlv4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NEHjfY9yUFSVIHHzd4F6			NICyNYxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	M371fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	NIm1c\|ZyUFSVIHHzd4F6			M37MOZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	MnHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MWjxTHRUKGG\|c3H5			Mmr0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	M2i3[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NYnXSGtveUiWUzDhd5NigQ>?			NH7YWVdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	NVf4fIFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MmHxdWhVWyCjc4PhfS=>			NFPGZolyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	M161TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUm5O\|AzLz5\|MEG5PVcxOjxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pT231-tau / pS202-tau / tau; PubMed: 30915013 Front Neurol SH-SY5Y-(P301L) cells were exposed for 6 h to a range of roscovitine concentrations. Cells were harvested and proteins were resolved by SDS-PAGE followed by western blotting. p-Rb / p-CDK2 / CDK2 / Cyclin D1 / Cyclin A2 / ERα / ERβ/ AIB1 / PELP1 ; PubMed: 21834972 Breast Cancer Res (a) The model cells MCF7, MCF7-TamR, MCF7-HER2, and MCF7-LTLTca were treated with roscovitine and the status of cell cycle regulators and the estrogen receptor (ERα) signaling proteins was analyzed by western blotting.	30915013 21834972
Immunofluorescence	CDK1 / Smek2 / FUBP1 / Cdc20 ; PubMed: 24534090 EMBO J A-D Validation of changes in chromatin affinity following Cdk inhibition of indicated candidates (2 h, 50 μM roscovitine) using Triton extraction and immunofluorescence (IF) in HeLa cells. Quantification of IF data was performed by measuring changes in signal intensities in Image J. E2F1 / FASN / Bmi1 / Cyclin D2 / CDK2 / CDK4 ; PubMed: 20890301 Oncogene Immunofluorescence analysis of E2F1, FASN, E2F1/Shh target Bmi1, cyclin D2, cdk 2, and cdk 4 in Pzp53med cells treated with DMSO (control) or the cdk inhibitor roscovitine (10 nM) for 18 hours.	24534090 20890301
Growth inhibition assay	Cell viability; PubMed: 29996940 J Exp Clin Cancer Res Cell viability assay on OVCAR5, OAW42, SKOV3 and NL3507 cells treated with roscovitine (2, 5, 10, 20, 40 μM) up to 96 h. Each point represents the mean of three replicates. Error bars, SD	29996940

体内研究

Roscovitine按50 mg/kg剂量作用于Ewing's肉瘤家族(ESFT)移植瘤，明显抑制肿瘤生长。^[4] Roscovitine作用于携带MCF7移植瘤的裸鼠，增强抗癌Doxorubicin抗癌效果,不会提高毒性，机制是使细胞周期停滞而不是引起凋亡。^[5]

激酶实验：^[1]	- 合并酶实验: 激酶活性实验在30^oC下buffer C中进行。从数据中除去空白值，在10分钟的温育期中测定渗透到蛋白受体中的磷酸摩尔数，来计算活性。对照组用适当稀释的DMSO处理。在一些情况下, SDS/PAGE后通过自动射线照相术测定底物磷酸化。p34^cdc2/cyclin B通过亲和色谱从 M期海星卵母细胞中纯化。使用 1 mg 组蛋白Hl/mL,在15 μM [γ-³²P]ATP存在时进行实验，终浓度为 30 μL。在 30^oC下温育10分钟, 25-μL上清液转移到Whatman P81磷酸纤维素纸上, 20秒后, 用10mL磷酸/L水冲洗过滤器5次，每次至少5分钟。湿式过滤器转移到 6 mL闪烁管,加入5 mL ACS闪烁液，使用Packard 计数器测定放射性。测定在10分钟温育期中组蛋白H1渗透放入磷酸摩尔数评估激酶活性或者最大活性百分数。感染不同杆状病毒的sf9昆虫细胞抽提物中再生p33^cdk2/cyclin A和p33^cdk2/cyclinE。Cyclins A 和E是谷胱甘肽S-转移酶融合蛋白，复合体从谷胱甘肽-琼脂糖珠上纯化。使用 1 mg/mL 组蛋白Hl/mL,在15 μM [γ-³²P]ATP存在时，进行激酶活性实验10分钟，终体积为30 μL，测定p34^cdc2/cyclin B激酶。p33^cdk5/p35从牛脑中纯化,除了Mono S-色层分离一步法。 Superose 12柱的活性片段汇集，终浓度为25 μg 酶/mL。使用1 mg/mL 组蛋白Hl, 在15 μM [γ-³²P]ATP存在时，进行激酶活性实验10分钟，终体积为 30 μL，测定p34^cdc2/cyclin B激酶。
细胞实验：^[1]	- 合并 Cell lines: 白血病, 非小细胞肺癌,结肠癌, 中枢神经系统肿瘤，恶性黑色素瘤,卵巢癌，肾癌, 前列腺癌，胸腺癌细胞系 Concentrations: 0.01到100 μM Incubation Time: 48小时 Method: 包括9种肿瘤类型的60种人类肿瘤细胞系培养24小时，然后用 0.01-100 μM Roscovitine持续处理48小时。进行sulforhodaminine B蛋白实验测评毒性。 (Only for Reference)
动物实验：^[4	- 合并 Animal Models: 右后侧皮下注射A4573细胞的CD1 nu/nu鼠 Dosages: ≤50 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	71 mg/mL (200.31 mM)
	Water	Insoluble
	Ethanol	''6 mg/mL
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% DMSO+10% Tween 80+20% N-N-dimethylacetamide+69% PEG 400	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Roscovitine (CYC202) SDF

分子量	354.45
化学式	C₁₉H₂₆N₆O
CAS号	186692-46-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	Seliciclib, R-roscovitine

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02649751	Terminated	Drug: Roscovitine\|Drug: Placebo	Cystic Fibrosis	University Hospital Brest\|ManRos Therapeutics\|Cyclacel Pharmaceuticals Inc.	February 22 2016	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How can I reconstitute the drug for in vivo studies?
回答：
S1153 in 1% DMSO+10% Tween 80+20% N-N-dimethylacetamide+PEG 400 is a clear solution which is okay for injection. And S1153 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension, which is fine for oral gavage.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

选择性强的CDK抑制剂

SNS-032 (BMS-387032) : CDK2-selective, IC50=48 nM.
活性最高的CDK抑制剂

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
用于临床的CDK抑制剂

Palbociclib (PD0332991) Isethionate : Phase III for Metastatic Breast Cancer.
最新的CDK抑制剂

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

研究领域

产品类型

定制您的化合物库

Roscovitine (CYC202)

客户使用Selleck生产的Roscovitine (CYC202)发表文献103篇：

产品安全说明书

CDK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Roscovitine (CYC202) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

常见问题及建议解决方法

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

相关CDK产品